WellSpring Pharmaceutical

WellSpring Pharmaceutical was a manufacturer and marketer of branded OTC health and personal care products in the United States and Canada. When Sentinel invested in WellSpring, it consisted of three businesses: a consumer portfolio of well-known OTC health and personal care brands; specialty prescription drugs; and contract manufacturing and packaging services for leading pharmaceutical companies. Under Sentinel’s ownership, WellSpring sharpened its focus by divesting its specialty Rx drugs and bolstering its consumer healthcare portfolio with three add-ons. In 2017, WellSpring sold its high-performing portfolio of OTC consumer brands, including Emetrol, Bonine, Bactine, GlaxalBase, and FDS. After the sale, WellSpring continued to operate WellSpring Pharma Services, its growing contract manufacturing business. With the sale of WellSpring Pharma in 2018, Sentinel completed its exit.